Our Nation Today

Personalized mRNA Melanoma Therapy Meets Goals in Phase 3 Trial

CAMBRIDGE, Mass. - An experimental, personalized mRNA treatment developed by Moderna and Merck reduced the risk of melanoma returning or spreading in a large Phase 3 study when it was added to the immunotherapy Keytruda, the companies...